The U.S. Food and Drug Administration (FDA) announced that it will take formal action against Hims & Hers, a telehealth provider that prescribes and ships compounded GLP-1 weight loss drugs. According to Reuters, the FDA indicated that it would block Hims' access to drug ingredients and refer the case to the Department of Justice for additional investigation. Hims recently scrapped plans to sell a compounded version of Novo Nordisk's Wegovy tablet for $49 per month.
Related Posts
Watch for those yellow jackets in fall
Yellow jackets are most likely to sting in the fall when their natural food source, other insects, is less abundant, so they gravitate to picnics,…
Good investment: dental care
If you visit your dentist on a regular basis, you are doing yourself a favor in four ways. First, you are saving your teeth so you can chew properly,…
January is National Blood Donor Month: Blood banks begin search for donors
For children, January is a month for sledding and building snowmen. For blood banks it is a time of searching. With snowstorms, holidays, increased…